幽门螺杆菌(Helicobacter pylori,Hp)是一种常见的致病菌,在我国Hp的感染率超过了50%,严重影响了国民生活质量。已有的研究表明,鼠李糖乳酪杆菌CCFM1259能够拮抗Hp,改善胃部健康,且透明质酸(hyaluronan,HA)是一种能够在人体内发挥重要生理功能的线性糖胺聚糖。该文通过Hp感染动物模型筛选对Hp具有拮抗效果的HA,并将其与CCFM1259复配,探究复配物在动物及临床上拮抗Hp的效果。动物实验结果表明,高分子质量HA(100~150 wDa)具有较好拮抗Hp作用,且高分子质量HA或复配物均能够显著降低感染小鼠体内Hp定殖量,减轻小鼠因Hp感染引起的胃部炎症。临床研究共有48名受试者全程参与。受试者每天2次服用HA或复配物,持续4周。临床试验结果表明,HA和复配物干预不影响受试者血常规及血液生化相关指标,提高了受试者Hp转阴率和有效率,其中复配物的效果优于单独使用HA。以上研究结果表明,高分子质量HA与鼠李糖乳酪杆菌CCFM1259组合物能够有效拮抗幽门螺杆菌感染,且不会对受试者产生不利影响。
Helicobacter pylori is a common pathogenic bacterium. The infection rate of H. pylori in China is more than 50%, which seriously affects the quality of life. Previous studies showed that Lacticaseibacillus rhamnosus CCFM1259 could antagonize H. pylori and improve gastric health. Hyaluronan (HA) is a kind of linear glycosaminoglycan which plays an important physiological function in human body. In this paper, a H. pylori infection animal model was used for screening the special HA which had antagonistic effect on H. pylori. Furthermore, the mixture contained selected HA and L. rhamnosus CCFM1259 was evaluated the antagonistic effects on H. pylori through animal and clinical studies. The results of animal experiments showed that high molecular weight HA (100-150 wDa) had a good antagonistic effect on H. pylori, which significantly reduced the colonization of H. pylori and gastric inflammation in mice infected H. pylori. And similar results were obtained in the mixture group. A total of 48 subjects participated in the clinical study. The subjects took HA or HA-probiotic powder twice a day for 4 weeks. No side effect in blood routine and blood biochemical indexes was observed in oral HA or HA-probiotic powder group. The eradication and effective rates of H. pylori were increased in both intervention groups and the effects of HA-probiotic compounds were better than that of HA. The above results showed that the compounds of high molecular weight HA and L. rhamnosus CCFM1259 could effectively antagonize H. pylori infection, and had no adversely effects on the subjects.
[1] MARSHALL B, WARREN J R.Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J].The Lancet, 1984, 232(8390):1311-1315.
[2] AMIEVA M, PEEK JR R M.Pathobiology of Helicobacter pylori-induced gastric cancer[J].Gastroenterology, 2016, 150(1):64-78.
[3] LANAS A, CHAN F K L.Peptic ulcer disease[J].The Lancet, 2017, 390(10094):613-624.
[4] DU L J, CHEN B R, KIM J J, et al.Helicobacter pylori eradication therapy for functional dyspepsia:Systematic review and meta-analysis[J].World Journal of Gastroenterology, 2016, 22(12):3486-3495.
[5] HOOI J K Y, LAI W Y, NG W K, et al.Global prevalence of Helicobacter pylori infection:Systematic review and meta-analysis[J].Gastroenterology, 2017, 153(2):420-429.
[6] OHNISHI N, YUASA H, TANAKA S, et al.Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse[J].Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(3):1003-1008.
[7] CHEY W D, LEONTIADIS G I, HOWDEN C W, et al.ACG clinical guideline:Treatment of Helicobacter pylori infection[J].American Journal of Gastroenterology, 2017, 112(2):212-239.
[8] CHEN L Y, XU W L, LEE A, et al.The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis:An open-label, randomized clinical trial[J].EBioMedicine, 2018, 35:87-96.
[9] 张美怡, 翟齐啸, 赵建新, 等.鼠李糖乳杆菌JS-SZ-2-1抗幽门螺杆菌感染的临床效果评价[J].食品与发酵工业, 2020, 46(23):29-34.
ZHANG M Y, ZHAI Q X, ZHAO J X, et al.Clinical efficacy evaluation of Lactobacillus rhamnosus JS-SZ-2-1 against Helicobacter pylori infection[J].Food and Fermentation Industries, 2020, 46(23):29-34.
[10] ZHENG X L, WANG B T, TANG X, et al.Absorption, metabolism, and functions of hyaluronic acid and its therapeutic prospects in combination with microorganisms:A review[J].Carbohydrate Polymers, 2023, 299:120153.
[11] 黄佳星, 刘语菲, 冯丽安, 等.透明质酸水凝胶在组织修复中的应用[J].离子交换与吸附, 2022, 38(1):87-94.
HUANG J X, LIU Y F, FENG L A, et al.Application of hyaluronic acid hydrogel in tissue engineering[J].Ion Exchange and Adsorption, 2022, 38(1):87-94.
[12] 张美怡. 具有抗幽门螺杆菌感染作用乳杆菌的筛选及其临床效果评价[D].无锡:江南大学,2020.
ZHANG M Y.Screening and clinical functional evaluation of Lactobacillus strains for their anti-Helicobacter pylori effects[D].Wuxi:Jiangnan University, 2020.
[13] HONG S S, LEE H A, KIM J Y, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacilllus paracasei HP7[J].Laboratory Animal Research, 2018, 34(4):216-222.
[14] 闫宗宝, 毛方圆, 单治国, 等.幽门螺杆菌感染对胃黏膜上皮细胞REDD1表达的影响及调控机制[J].陆军军医大学学报, 2022, 44(5):413-420.
YAN Z B, MAO F Y, SHAN Z G, et al.Effect and mechanism of H.pylori in regulation of REDD1 expression in gastric mucosa[J].Journal of Army Medical University, 2022, 44(5):413-420.
[15] 刘阳. Akkermansia muciniphila菌对肠道屏障的调节作用及相关基因研究[D].无锡:江南大学,2021.
LIU Y.The research on the regulation of Akkermansia muciniphila strains on intestinal barrier and related functional genes[D].Wuxi:Jiangnan University, 2021.
[16] SOUISSI S, MAKNI C, BELHADJ AMMAR L, et al.Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis:Results of a prospective study[J].Helicobacter, 2022, 27(4):e12910.
[17] HENRIQUES P C, COSTA L M, SEABRA C L, et al.Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice[J].Acta Biomaterialia, 2020, 114:206-220.
[18] 杭兴伟, 增田泰伸, 木村守, 等.硫酸氨基葡萄糖对口服透明质酸缓解小鼠佐剂性关节炎的增效作用[J].食品科学, 2015, 36(5):189-194.
HANG X W, YASUNOBU M, MAMORU K, et al.Synergism of glucosamine sulfate in relieving effect of hyaluronic acid by oral administration on mice with adjuvant arthritis[J].Food Science, 2015, 36(5):189-194.
[19] PATEL S K.Diagnosis of Helicobacter pylori:What should be the gold standard?[J].World Journal of Gastroenterology, 2014, 20(36):12847.
[20] HOLZ C, BUSJAHN A, MEHLING H, et al.Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648:A pilot study[J].Probiotics and Antimicrobial Proteins, 2015, 7(2):91-100.
[21] MEHLING H, BUSJAHN A.Non-viable Lactobacillus reuteri DSMZ 17648 (pylopassTM) as a new approach to Helicobacter pylori control in humans[J].Nutrients, 2013, 5(8):3062-3073.
